Unitaid is investing US$59 million in the IMPAACT4TB (Increasing Market and Public health outcomes through scaling up Affordable Access models of short Course preventive therapy for TB) project.
 
 
 

This study is led and sponsored by the Aurum Institute. The study is a parallel, two-part, open-label, individually randomized, pragmatic trial among HIV-positive individuals.
 
 
 
 

The purpose of this study is to compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing confirmed or probable active tuberculosis (TB) during 96 weeks of follow-up among high-risk household contacts (HHCs) of
adults with multidrug-resistant
tuberculosis (MDR-TB)
(index cases).

The TB Sequel consortium is a research consortium that was built on pre-existing research collaborations within the TTU-TB of the German Center for Infection Research (DZIF) and between LMU and different African Sites (such as the PanACEA-consortium or
MaTuTU-project).
 
 

EHPSA commissioned Aurum Research Institute to assess the policies and practices related to HIV and TB data collection and surveillance in correctional facilities of Malawi, Namibia, Lesotho, Swaziland, and Zambia.
 
 
 
 

The Aurum Institute collaborates with CHAPS and the Bantwana Initiative to increase voluntary medical male circumcision VMMC among adolescent boys and young men ages 10-29 as a mechanism for HIV prevention in Eswatini.